ArticleEuropean journal of heart failure2022
An international Delphi consensus regarding best practice recommendations for hyperkalaemia across the cardiorenal spectrum.
Article in European journal of heart failure, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 40 citations in OpenAlex.
- Overcoming Hyperkalaemia as a Barrier to Achieving Optimal RAASi Therapy and Cardiorenal Protection in Individuals with Cardiorenal Disease: A Podcast Discussion.Advances in therapy · 2026Article
- Comprehensive Management of Hyperkalaemia in Patients with Chronic Kidney Disease and Cardiovascular Conditions: Expert Recommendations from Mexico.Cardiac failure review · 2026Review
- Effects of sodium zirconium cyclosilicate on the quality of life of patients with hyperkalemia undergoing hemodialysis: Y-QOL study design.BMC nephrology · 2025Article
- Prescription of ACE-Is/ARBs in patients with cardio-renal disease: a multicenter retrospective cohort study from the REPOSI registry.Internal and emergency medicine · 2025Observational
- Duration of sodium zirconium cyclosilicate treatment and continuation of RAASi therapy after a hyperkalaemia episode.ESC heart failure · 2025Observational
- The burden of hyperkalaemia in chronic kidney disease: a systematic literature review.Clinical kidney journal · 2025Article
- Frequency of hyperkalemia during optimization of guideline-directed medical therapy in ambulatory patients with HFrEF.Frontiers in cardiovascular medicine · 2025Article
- Sodium Zirconium Cyclosilicate for Renin-Angiotensin-Aldosterone System Inhibitor Optimization in Patients with Heart Failure with Reduced Ejection Fraction: A Retrospective Analysis.Cardiology and therapy · 2024Article
- Cost-Utility of Real-Time Potassium Monitoring in United States Patients Receiving Hemodialysis.Kidney international reports · 2024Article
- Design and cohort characteristics of TRACK, a prospective study of hyperkalaemia management decision-making.Clinical kidney journal · 2024Article
- Hyperkalaemia-related reduction of RAASi treatment associates with more subsequent inpatient care.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024Article
- Maintained renin-angiotensin-aldosterone system inhibitor therapy with sodium zirconium cyclosilicate following a hyperkalaemia episode: a multicountry cohort study.Clinical kidney journal · 2024Article
- Article
- Recommendations for the management of hyperkalemia in patients receiving renin-angiotensin-aldosterone system inhibitors.Internal and emergency medicine · 2024Review
- Article
- Management of hyperkalemia: Expert consensus from Kuwait - a Modified Delphi Approach.International journal of nephrology and renovascular disease · 2024Article
- A Delphi consensus on the management of anticoagulation in the COVID-19 pandemic: the MONACO study.Cardiovascular diagnosis and therapy · 2023Review
- Serum potassium level and mineralocorticoid receptor antagonist dose in a large cohort of chronic heart failure patients.ESC heart failure · 2023Article
- Corrigendum to: 'An international Delphi consensus regarding best practice recommendations for hyperkalaemia across the cardiorenal spectrum' and articles listed below.European journal of heart failure · 2023Article
- Safety and efficacy of novel potassium binders for chronic hyperkalemia: a systematic review and meta-analysis of randomized controlled trials.Proceedings (Baylor University. Medical Center)Review
Corrections and comments
- Erratum issued
Authors and funding
8 authors at 8 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsRenin-angiotensin-aldosterone system inhibitors (RAASi) are guideline-recommended therapy for individuals with cardiorenal disease. They are associated with increased risk of hyperkalaemia, a common and life-threatening disorder for this population. RAASi-induced hyperkalaemia often leads to dose reduction or discontinuation, reducing cardiorenal protection. Guideline recommendations differ between specialties for the clinical management of hyperkalaemia. Using a modified Delphi method, we developed consensus recommendations for optimal management of hyperkalaemia in adults with cardiorenal disease. METHODS AND
resultsAn international steering group of cardiologists and nephrologists developed 39 statements regarding hyperkalaemia care, including risk factors and risk stratification, prevention, correction, and cross-specialty coordination. Consensus was determined by agreement on an online questionnaire administered to cardiorenal specialists across Europe and North America. The threshold for consensus agreement was established a priori by the steering group at 67%. Across November 2021, 520 responses were received from Canada (n = 50), France (n = 50), Germany (n = 54), Italy (n = 58), Spain (n = 57), the UK (n = 49), and the US (n = 202); 268 from cardiologists and 252 from nephrologists. Twenty-nine statements attained very high agreement (≥90%) and 10 attained high agreement (≥67%-<90%), with strong alignment between cardiologists and nephrologists.
conclusionA high degree of consensus regarding hyperkalaemia evaluation and management exists among healthcare professionals. Based on high levels of agreement, the steering group derived six key recommendations for hyperkalaemia prevention and management in people with cardiorenal disease. Future studies examining the quality of hyperkalaemia care delivery are required.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.